verastem

Focus on Mesothelioma in Pharmaceutical Company Investor Meeting

On July 10, during the research and development portion of the Verastem, Inc.’s investor meeting, Mary Hesdorffer, APRN, the executive director of the Mesothelioma Applied Research Foundation, was a featured speaker. In her talk, Ms. Hesdorffer focused on the need for clinical trials to increase the number of viable therapeutic options for mesothelioma.
According to their website, […]



BREAKING NEWS: New Clinical Trial Opening

PRESS RELEASE
Contact Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com
CAMBRIDGE, MA – Sep. 10, 2013 – Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the initiation of COMMAND (Control Of Mesothelioma with MAiNtenance Defactinib). COMMAND is a registration-directed trial of lead cancer stem cell inhibitor […]